Skip to Main Content

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Conditions

Immune System

Phase III

What is the purpose of this trial?

Brief Summary:

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.

  • Trial with
    Janssen Pharmaceuticals
  • Start Date
    06/30/2019
  • End Date
    01/21/2021
Trial Image

For more information about this study, contact:

Allison Ready

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/02/2019
  • Study HIC
    #2000022990